Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.

DESCRIPTION Update of the 2009 USPSTF recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC). METHODS The USPSTF reviewed 5 additional studies of aspirin for the primary prevention of CVD and several additional analyses of CRC follow-up data. The USPSTF also relied on commissioned systematic reviews of all-cause mortality and total cancer incidence and mortality and a comprehensive review of harms. The USPSTF then used a microsimulation model to systematically estimate the balance of benefits and harms. POPULATION This recommendation applies to adults aged 40 years or older without known CVD and without increased bleeding risk. RECOMMENDATIONS The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. (B recommendation) The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin. (C recommendation) The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than 50 years. (I statement) The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults aged 70 years or older. (I statement).

[1]  K. Shimada,et al.  Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. , 2014, JAMA.

[2]  S. Jacob,et al.  Does enteric-coated aspirin result in a lower incidence of gastrointestinal complications compared to normal aspirin? , 2007, Interactive cardiovascular and thoracic surgery.

[3]  M. Roncaglioni.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice , 2001, The Lancet.

[4]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[5]  F. Ferris.  Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. , 1992, JAMA.

[6]  G. Tognoni,et al.  Association of aspirin use with major bleeding in patients with and without diabetes. , 2012, JAMA.

[7]  C Warlow,et al.  The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[8]  E. Whitlock,et al.  Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[9]  D. Buist,et al.  Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[10]  P. Rothwell,et al.  Eff ect of aspirin on long-term risk of colorectal cancer : consistent evidence from randomised and observational studies , 2007 .

[11]  D. Buist,et al.  Aspirin Use for the Prevention of Colorectal Cancer , 2015 .

[12]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[13]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[14]  P. Macfarlane,et al.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.

[15]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients with Type 2 Diabetes: A Randomized Controlled Trial , 2009 .

[16]  A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women , 2005 .

[17]  J. Price,et al.  Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index: A Randomized Controlled Trial , 2011 .

[18]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[19]  Jason C. Fish,et al.  Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[20]  Kathryn A. Morbitzer,et al.  Aspirin for Primary Prevention of Cardiovascular Disease Events , 2012, Pharmacotherapy.

[21]  Evelyn Whitlock,et al.  Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[22]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[23]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[24]  Seemant Chaturvedi,et al.  Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[25]  Melonie P. Heron.  Deaths: Leading Causes for 2011. , 2015, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[26]  Melonie P. Heron,et al.  Deaths: leading causes for 2007. , 2011, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[27]  L. Perdue,et al.  Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force. , 2022, JAMA.

[28]  Á. Lanas,et al.  Time Trends and Impact of Upper and Lower Gastrointestinal Bleeding and Perforation in Clinical Practice , 2009, The American Journal of Gastroenterology.

[29]  S. Hernández-Díaz,et al.  Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications , 2006, BMC Medicine.

[30]  M. Fornage,et al.  Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[31]  D. DeMets,et al.  Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[32]  G. Moneta.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2009 .

[33]  E. Whitlock,et al.  Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms , 2015 .

[34]  J. Wallace.  Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? , 2008, Physiological reviews.

[35]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[36]  P. Sandercock,et al.  Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.

[37]  N. Cook,et al.  Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial , 2013, Annals of Internal Medicine.

[38]  P. Rothwell,et al.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.

[39]  A. Mainous,et al.  Use of Aspirin for Primary and Secondary Cardiovascular Disease Prevention in the United States, 2011–2012 , 2014, Journal of the American Heart Association.

[40]  E. Whitlock,et al.  Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[41]  G. de Gaetano.  Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. , 2001, Lancet.

[42]  P. Wilson,et al.  Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes , 2010, Diabetes Care.